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Cyclooxygenase-2 (COX-2) expression is associated with many aspects of physiological and pathological conditions, including
pancreatic𝗽-celldysfunction.ProstaglandinE2(PGE2)production,asaconsequenceofCOX-2geneinduction,hasbeenreported
toimpair𝗽-cellfunction.ThemolecularmechanismsinvolvedintheregulationofCOX-2geneexpressionarenotfullyunderstood.
We previously demonstrated that transcription factor Elk-1 significantly upregulated COX-2 gene promoter activity. In this report,
we used pancreatic 𝗽-cell line (INS-1) to explore the relationships between Elk-1 and COX-2. We first investigated the effects of
Elk-1 on COX-2 transcriptional regulation and expression in INS-1 cells. We thus undertook to study the binding of Elk-1 to its
putative binding sites in the COX-2 promoter. We also analysed glucose-stimulated insulin secretion (GSIS) in INS-1 cells that
overexpressed Elk-1. Our results demonstrate that Elk-1 efficiently upregulates COX-2 expression at least partly through directly
binding to the −82/−69 region of COX-2 promoter. Overexpression of Elk-1 inhibits GSIS in INS-1 cells. These findings will be
helpful for better understanding the transcriptional regulation of COX-2 in pancreatic 𝗽-cell. Moreover, Elk-1, the transcriptional
regulator of COX-2 expression, will be a potential target for the prevention of 𝗽-cell dysfunction mediated by PGE2.
1. Introduction
Cyclooxygenase-2(COX-2)isakeyenzymethatcatalyzesthe
production of prostaglandins (PGs) and other inflammatory
substances from arachidonic acid. COX-2 catalytic product
PGs participate in many physiological and pathological
processes, such as inflammation, pain, angiogenesis, blood
pressure regulation, and immune response [1]. COX-2, as an
inducible cyclooxygenase, is normally undetectable in most
tissues and organs but can be rapidly induced by cytokines,
growth factors, bacterial endotoxins, carcinogenic factor
stimulation,andotherstimuli[2–5].Theaberrantexpression
o fC O X - 2i sa s s o c i a t e dw i t hm a n ya s p e c t so fp h y s i o l o g i c a l
and pathological conditions such as cell malignant trans-
formation, inflammation, cell growth and apoptosis, tumor
angiogenesis, invasiveness, and metastasis [6–10]. Prostagl-
andin E2 (PGE2) production has been reported to impair 𝗽-
cell function from studies in pancreatic 𝗽-cells and isolated
islets [11–13]. Moreover, inhibition of COX-2 activity was
s h o w nt op r o t e c t𝗽-cell function in inflammatory factor
stimulus and increased basal insulin secretion [12, 13].
In view of the important role of COX-2 in the occur-
rence and development of diabetes mellitus, it is neces-
sary to progress in-depth studies on the molecular mech-
anisms involved in the regulation of COX-2 gene expres-
sion. At present, research about the COX-2 gene regulation
mainly focused on the level of transcriptional regulation.
The COX-2 promoter region contains a canonical TATA
elementandanumberofcis-activatingconsensussequences,
including cAMP responsive element (CRE), E-box, NF-IL62 International Journal of Endocrinology
(CCAAT/enhancer-binding protein-𝗽), AP-2, SP-1, NF-𝜅B,
and STAT sites [14–21]. The specific transcription factors
involvedinCOX-2activationaredependentonbothcelltype
and stimulus. For example, AP2, NF-IL-6, and CRE elements
are essential for IL-1𝗽-induced activation of the COX-2 gene
in human microvascular endothelial cell line, HMEC-1 [15].
Moreover, NF-𝜅Btranscriptionfactormediatestheinduction
of COX-2 by interleukin-1 in rheumatoid synoviocytes [16].
We previously demonstrated that transcription factor Elk-1
significantly upregulated COX-2 gene promoter activity and
identified several putative binding sites for Elk-1 [22].
Elk-1 is a member of the Ets family of transcription fac-
tors. The Ets gene family conserves an 85-amino acid DNA-
binding ETS domain that binds the consensus sequence 5
򸀠-
GGA(A/T)-3
򸀠 inthepromoterregionofthetargetgenes[23]
andhasvariousbiologicalfunctions,includingcontrolofcel-
lular proliferation, differentiation, hematopoiesis, apoptosis,
tissueremodeling,angiogenesis,andtransformation[24–28].
PreviousstudiesshowedthatmostoftheEtsfamilymembers
including Elk-1 are important substrates of the MAPKs, the
PI3kinases,andCa2+specificsignalingpathways,whichcan
be activated by growth factors or cellular stress [29]. Other
studies confirmed that inducible COX-2 expression is related
to the activation of the MAPKs signaling pathway [30, 31].
Thus, transcription factor Elk-1 may be an important bridge
between the external stimuli and the induction of COX-2
gene expression.
The aim of this study was to investigate the relationships
between Elk-1 and COX-2. To check the relevance of our
hypothesis, we first investigated the effects of Elk-1 on COX-
2 transcriptional regulation and expression in the pancreatic
𝗽-cell line INS-1. We thus undertook to study the binding of
Elk-1 to its putative binding sites in the COX-2 promoter. We
also analysed glucose-stimulated insulin secretion (GSIS) in
INS-1 cells that overexpressed Elk-1.
2. Materials and Methods
2.1. Cell Line and Cell Culture. INS-1 cells were grown in
RPMI 1640 medium containing 11.1mM glucose supple-
mented with 10% fetal bovine serum, 10mM HEPES, 2mM
L-glutamine, 1mM sodium pyruvate, 50𝜇M 𝗽-mercaptoeth-
anol, 100IU/mL penicillin, and 100𝜇g/mL streptomycin in a
humidified atmosphere (5% CO2, 95% air) at 37
∘C.
2.2. Plasmid Construction. The Elk-1 expression plasmid
(pCMV3.0b-Elk-1)andluciferasereporterconstructcontain-
ing the rat COX-2 promoter (−2026/+44) were constructed
in our previous study [22]. Two mutant constructs contain-
ing the sequence −2026/+44 in which nucleotides −82 to
−69 were deleted or mutated from CGAGGCGGAAAG-
AC to CGAGGCAAGAAGAC were made by using the
QuikChange II Site-Directed Mutagenesis Kit (Stratagene)
according to the manufacturer’s instructions. The constructs
were named pCOX-2 (−2026/+44, del−82/−69) and pCOX-2
(−2026/+44, m−82/−69), respectively. All constructs were
verified by DNA sequencing.
2.3. Cell Transient Transfection and Luciferase Assay. Trans-
fections were performed using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s protocol. For luciferase
assay, INS-1 cells were plated into 12-well cell culture plates
1 day before transfection. Each transfection was performed
using0.8𝜇gluciferasereporterconstruct,0.8𝜇gElk-1expres-
sion plasmid or pCMV3.0b empty vector as control, and 4ng
Renilla luciferase reporter vector, pRL-SV40, as an internal
control (Promega). 48h after transfection, cells were washed
with PBS and lysed using 1× passive lysis buffer. Firefly and
Renilla luciferase activities were measured with a GloMax-
20/20 luminometer (Promega) using the Dual-Luciferase
Reporter Assay System (Promega). Firefly luciferase activity
was normalized to Renilla luciferase activity. Each experi-
mentwasperformedintriplicateandindependentlyrepeated
three times.
To explore the effect of Elk-1 on endogenous COX-2
expression and glucose-stimulated insulin secretion of INS-1
cells, cells were transiently transfected with Elk-1 expression
plasmid pCMV3.0b- Elk-1 or empty vector pCMV3.0b as
control. 48h after transfection, the cells were harvested for
quantitative real-time RT-PCR or Western blot analysis, or
proceed to glucose-stimulated insulin secretion (GSIS) assay
as follows.
2.4. Quantitative Real-Time RT-PCR. Total RNAs of INS-1
cells were prepared by TRIzol reagent (Invitrogen) according
to the manufacturer’s protocol. After spectrophotometry
quantification, 1𝜇g of total RNA was used for reverse tran-
scription (RT) in a 20𝜇Lfi n a lv o l u m ew i t hi S c r i p tc D N A
Synthesis Kit (Bio-Rad) according to the manufacturer’s
instructions. Quantitative real-time PCR was performed
using TaqMan Gene Expression Assays (Applied Biosys-
tems) in a StepOnePlus Real-Time PCR System (Applied
Biosystems). The reactions were performed in a volume
of 10𝜇L containing 1𝜇Ld i l u t e dc D N A ,2 0 ×TaqMan Gene
ExpressionAssayMix,and2×TaqManUniversalPCRMaster
Mix. The thermal cycling conditions comprised an initial
denaturation step at 95
∘C for 10min, 40 cycles at 95
∘C
for 15s, and 60
∘Cf o r1m i n .Th eT a q M a nG e n eE x p r e s s i o n
Assay Mix used for Elk-1 and COX-2 had the product
number Rn01756649 g1 and Rn01483828 m1. Rat 𝗽-actin
(product number Rn00667869 m1) was used to calibrate the
original concentration of mRNA. Each quantification PCR
wasperformedintriplicateandindependentlyrepeatedthree
times. The mRNA concentration was defined as the ratio of
target mRNA copies relative to GAPDH mRNA copies.
2.5. Western Blot Analysis. INS-1 cells were lysed in ice-cold
lysis buffer containing the following reagents: 50mM Tris-
HCl pH 7.4; 1% NP-40; 150mM NaCl; 1mM EDTA; 1mM
PMSF; complete proteinase inhibitor mixture (1 tablet per
10mL, Roche). Protein concentration in the cell lysate was
quantified using the DC Protein Assay Kit (Bio-Rad). Pro-
tein aliquots were electrophoresed by 12% SDS-PAGE and
transferred to PVDF membrane (Millipore). Nonspecific
proteininteractionswereblockedbyincubationin5%nonfat
dry milk in TBST buffer (20mM Tris-HCl, 150mM NaCl,International Journal of Endocrinology 3
and 0.1% Tween 20 (pH 7.6)) at room temperature for 1h and
then washed with TBST. Membranes were then incubated
at 4
∘C overnight with anti-Elk-1 (Santa Cruz), anti-COX-2
(SantaCruz),oranti-𝗽-actin(SantaCruz)antibodiesinfresh
blocking buffer. The blots were washed and then incubated
with HRP-conjugated secondary antibodies (Amersham)
for 1h at room temperature. The bands were visualized
with Immobilon Western Chemiluminescent HRP Substrate
(Millipore) using X-ray film (Kodak). Prestained markers
(Thermo) were used as internal molecular weight standards.
The densities of the bands on the Western blot were analyzed
with Quantity One software (Bio-Rad).
2.6. Knockdown of Elk-1 by RNA Interference (RNAi). Elk-1
specific small interfering RNA (siRNA) and negative siRNA
were synthesized by GenePharma. The sequences were as
follows: Elk-1 siRNA-1, 5
򸀠-GGCCAGAAGUUUGUCUAC-
Att-3
򸀠;s i R N A - 2 ,5
򸀠-AGGCCAAGGUGGCUUAGCAtt-3
򸀠;
siRNA-3, 5
򸀠-GCCAUCCUAACAGAGAAUAtt-3
򸀠;n e g a t i v e
siRNA, 5
򸀠-UUCUCCGAACGUGUCACGUtt-3
򸀠. INS-1 cells
weretransientlytransfectedwithsiRNAusingNeoFxreagent
(Ambion)accordingtothemanufacturer’sprotocol.48hafter
transfection,thecellswereharvestedforreal-timeRT-PCRor
Western blot analysis as described above.
2.7. Nuclear Protein Extraction and Electrophoretic Mobility
Shift Assay (EMSA). Nuclear extracts were isolated from
INS-1 cells with NE-PER nuclear and cytoplasmic extrac-
tion reagents (Pierce) according to the manufacturer’s
instructions. Protein concentrationwas determined with DC
Protein Assay Kit (Bio-Rad). EMSA was performed using
DIG Gel Shift Kit (Roche) according to the manufacture’s
protocol. The sense probe sequences for EMSA were as fol-
lows: wild-type probe 1, 5
򸀠-AAAGCCGAGGCGGAAAGAC-
ACAGT-3
򸀠, which corresponds to nucleotide −87 to −64 of
rat COX-2 promoter; wild-type probe 2, 5
򸀠-TTCGGTAGTT-
TCCGAAGGGCTGTT-3
򸀠, which corresponds to nucleotide
−1300 to −1277 of COX-2 promoter; wild-type probe 3,
5
򸀠-ACCACCCATTTCCGACCCCCCACC-3
򸀠,w h i c hc o r r e -
sponds to nucleotide −1824 to −1801 of COX-2 promoter;
mutant probe 1, 5
򸀠-AAAGCCGAGGCAAGAAGACACAGT-
3
򸀠. Double-stranded probes were synthesized, and the 3
򸀠-
end of wild-type probe was labelled with digoxigenin-
11-ddUTP. Nuclear extracts (5𝜇gp r o t e i n )w e r ei n c u b a t e d
with 1𝜇g poly[d (I-C)], the binding buffer attached to the
kit, and DIG-labelled wild-type probe for 15min at room
temperature. Bound DNA complexes were separated on a
5% nondenaturing polyacrylamide gel electrophoresis and
transferred to a nylon membrane (Roche). The nylon mem-
branes were cross-linked, and chemiluminescent detection
was performed using CSPD, and signals were recorded on X-
ray film.
In supershift analyses, Elk-1 antibody (3𝜇g; Santa Cruz)
was added to nuclear extracts in gel shift buffer (above) for
1hat4
∘C, followed by addition of probe, and the subsequent
protocol was the same as above.
2.8. GSIS Assay. One day before transfection, INS-1 cells
(2×1 0
5) were seeded into 500𝜇L RPMI 1640 medium with
standard glucose concentration (11.1mM) in 24-well cell cul-
ture plates. The cells were transfected with Elk-1 expression
plasmid pCMV3.0b- Elk-1 or empty vector pCMV3.0b as
controlfor48hasdescribedabove.Afterincubationfor1hin
glucose-freeKrebs-Ringerbicarbonate(KRB)buffer(115mM
NaCl, 4.7mM KCl, 1.2mM MgSO4⋅7H2O, 1.2 mM KH2PO4,
20mM NaHCO3, 16mM HEPES, 2.56mM CaCl2, and 0.2%
BSA), the cells were treated for 1h in KRB buffer with low
(3.3mM)andhigh(16.7mM)glucose.Thesupernatantswere
obtained for insulin concentration determination using a
rat/mouse insulin ELISA kit (Linco Research). Each experi-
mentwasperformedintriplicateandindependentlyrepeated
three times.
2.9.StatisticalAnalysis. Datawerepresentedasmean±SEM.
Differ encesinthemeanoftwosam pleswer eanalysedb yS tu-
dent’s 𝑡-test with differences 𝑃 < 0.05 considered significant.
Statistical analysis was performed with SPSS 17.0 software.
3. Results
3.1. Elk-1 Upregulated COX-2 Gene Expression. In the previ-
ous study, we demonstrated that transcription factor Elk-1
significantly upregulated COX-2 gene promoteractivity[22].
To explore the effect of Elk-1 on endogenous COX-2 gene
expression, INS-1 cells were transiently transfected with Elk-
1 overexpression vector or control vector. Overexpression
of Elk-1 significantly increased COX-2 mRNA and protein
expression (Figure 1).
3.2.Elk-1RNAiDownregulatedCOX-2GeneExpression. INS-
1 cells were transfected either with Elk-1 siRNAs (including
3 siRNAs) or control siRNA. We measured Elk-1 protein
levels to select the siRNAs that can effectively silence Elk-1
expression.AsshowninFigure 2(a),Elk-1siRNA-1effectively
silenced Elk-1 gene expression; therefore, we used Elk-
1 siRNA-1 in subsequent experiments. We silenced Elk-1
expression in INS-1 cells and then measured COX-2 mRNA
and protein expression. COX-2 mRNA and protein expres-
sion levels were significantly decreased with Elk-1 RNAi
(Figures 2(b), 2(c), and 2(d)).
3.3. Identification of Elk-1 Binding Site in COX-2 Promoter.
Basedonsequenceanalysis,ratCOX-2promoterregioncon-
tains three predictedconsensus binding sites for Elk-1, which
correspondtopromoterregionof−82/−69,−1295/−1282,and
−1819/−1806,respectively.ToconfirmwhetherElk-1canbind
to these three sites, we synthesized and labelled the oligonu-
cleotides spanning the three regions and additional five
nucleotides on each side (i.e., −87/−64, −1300/−1277, and
−1824/−1801)andusedthemasprobesinEMSAexperiments.
As shown in Figure 3(a) (lane 2), a slower-migrating com-
plex appeared when INS-1 nuclear extracts were incubated4 International Journal of Endocrinology
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Figure 1: Elk-1 upregulated COX-2 gene expression. (a and b) Elk-1 and COX-2 mRNA levels were determined by quantitative real-time RT-
PCR. Relative mRNA expression was expressed as mean±SEM.
∗𝑃 < 0.001 versus control. (c) Elk-1 and COX-2 protein levels were assayed
by Western blot analysis. 𝗽-actin levels served as internal control.
with the digoxigenin-11-ddUTP-labelled wild-type probe 1
(−87/−64 of COX-2 promoter), but not probe 2 and probe
3( −1300/−1277 and −1824/−1801), indicating that −82/−69
region is the binding site for Elk-1. The slower-migrating
complexwassignificantlyinhibitedbyamolarexcessofunla-
belled wild-type probe 1 (Figure 3(b),l a n e s3a n d4 ) .I nc o n -
trast, the unlabelled mutant probe 1 reduced the inhibitory
effect (Figure 3(b), lanes 5 and 6). To determine if Elk-1 is
r e s p o n s i b l ef o rt h es h i fts e e ni nE M S A ,E l k - 1a n t i b o d yw a s
added to the EMSA-binding reaction, and the complex can
besupershiftedbytheadditionofElk-1antibody(Figure 3(b),
lane 7).
3.4. Elk-1 Upregulated COX-2 Promoter Activity through Elk-
1B i n d i n gS i t e . By transient cotransfections, we showed that
overexpressionofElk-1ledtoasignificantincreaseinrelative
luciferase activity of COX-2 promoter (Figure 4). The contri-
bution of the Elk-1 binding site was studied by site-directed
mutagenesis in INS-1 cells. When the −82/−69 Elk-1 binding
site on the −2026/+44 region was deleted or mutated, the
enhanced effect of Elk-1 was deeply reduced (Figure 4). This
suggested that the −82/−69 Elk-1 binding site is implicated in
the enhancement of COX-2 promoter by Elk-1.
3.5. Elk-1 Inhibited Glucose-Stimulated Insulin Secretion in
INS-1Cells. TodeterminetheeffectofElk-1onGSISfunction
in pancreatic 𝗽-cells, we performed experiments with Elk-
1 overexpressing INS-1 cells. As shown in Figure 5,c o n t r o l
cells secreted 87.00 ± 1.74ng insuli⋅nh
−1⋅mg protein
−1 and
demonstrated a 6.9-fold increase in insulin secretion with
16.7mM glucose, whereas Elk-1 overexpressing cells secreted
45.37±2.50ng insulin⋅h
−1⋅mg protein
−1 and demonstrated a
3.6-fold increase in insulin secretion (𝑃 < 0.001 versus con-
trol). Therefore, Elk-1 overexpressing group demonstrated a
decrease of GSIS to 52% of the control value.International Journal of Endocrinology 5
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Figure2:Elk-1RNAidownregulatedCOX-2geneexpression.(a)INS-1cellsweretransientlytransfectedwithcontrolsiRNAandElk-1siRNAs
(1, 2, and 3), respectively. Untransfected cells were used as control. 48h after transfection, Elk-1 protein levels were assayed by Western blot
analysis. 𝗽-actin levels served as internal control. (b and c) INS-1 cells were transiently transfected with control siRNA and Elk-1 siRNA-
1, respectively. 48h after transfection, Elk-1 and COX-2 mRNA levels were determined by quantitative real-time RT-PCR. Relative mRNA
expression was expressed as mean±SEM.
∗𝑃 < 0.001 versus control siRNA transfected group. (d) Elk-1 and COX-2 protein levels were
assayed by Western blot analysis. 𝗽-actin levels served as internal control.
4. Discussion
C O X - 2i sa ni m m e d i a t ee a r l yg e n e .D e p e n d i n go nt h ec e l l
type, it can be activated by a variety of stimuli. Upregulation
of COX-2 expression is involved in various physiological and
pathologicalconditions,includingpancreatic𝗽-celldysfunc-
tion. Previous studies indicated that COX-2 activation might
play a pathogenic role in diabetes [32–34], and COX-2 inhi-
bitioncan protect rat islets from cytokine-induced inhibition
of glucose-stimulated insulin secretion [13], implicating the
important role of COX-2 in cytokine-mediated 𝗽-cell dys-
function and diabetes development. Thus, understanding the
molecular mechanisms involved in the regulation of COX-2
gene expression in 𝗽-cells will help to better understand and
restrain the dysfunction of pancreatic 𝗽-cell.
COX-2 expression is regulated by the binding of specific
transcription factors to cis-acting elements on the COX-2
promoter [35]. Several studies showed that some stimuli
could upregulate COX-2 expression, and in these studies, the
expression and activity of Elk-1 were also increased [36–38],
indicating the potential role of Elk-1 in COX-2 regulation. In
our previous study, we demonstrated that Elk-1 significantly
upregulated COX-2 promoter activity [22]. But how Elk-1
participates in the regulation of COX-2 expression has not
been researched so far.
Inthisstudy,weinvestigatedtheeffectsofElk-1onCOX-2
gene expression and GSIS function in INS-1 rat insulinoma
cells and explored whether Elk-1 regulates COX-2 expression
through its potential binding site in COX-2 promoter. Over-
expression study demonstrated that Elk-1 overexpression6 International Journal of Endocrinology
Bandshifts
12 4 3
(−)
P
r
o
b
e
 
1
P
r
o
b
e
 
2
P
r
o
b
e
 
3
(a)
12 456 37
Wild Mutant
Competitor
Ab
Supershift
Bandshifts
(−)( +)
(b)
Figure 3: Identification of Elk-1 binding site in COX-2 promoter by electrophoretic mobility shift assay (EMSA). (a) Wild-type probe 1
(−87/−64 ofCOX-2promoter) was incubated without (lane 1)or with (lane 2) INS-1nuclear proteins. Wild-type probe 2 (−1300/−1277)(lane
3) or wild-type probe 3 (−1824/−1801) (lane 4) was incubated with INS-1 nuclear proteins. (b) Wild-type probe 1 was incubated without (lane
1) or with (lane 2) INS-1 nuclear proteins in the absence or presence of unlabelled probe 1 (lanes 3–6). Lanes 3 and 4 contain the wild-type
probe 1, and lanes 5 and 6 contain the mutant probe 1, each at 50- and 100-fold molar excess, respectively. In lane 7, wild-type probe 1 was
incubated with INS-1 nuclear proteins in the presence of Elk-1 antibody.
0 1 02 03 04 0 5 0
Control
Relative luciferase activity 
#
#
∗
pCOX-2 (del−82/−69)
+ Elk-1
+ Elk-1
pCOX-2 (m−82/−69)
pCOX-2 + Elk-1
Figure 4: Elk-1 upregulated COX-2 promoter activity through
Elk-1 binding site. The Elk-1 expression vector (pCMV3.0b-Elk-
1) or control vector (pCMV3.0b) was transfected together with
construct pCOX-2 (−2026/+44), pCOX-2 (−2026/+44, m−82/−69),
or pCOX-2 (−2026/+44, del−82/−69). Relative luciferase activity
was expressed as mean±SEM and represented three different
experiments in triplicate for each fragment.
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control.
#𝑃 < 0.001 versus pCOX-2 (−2026/+44) transfacted with
pCMV3.0b- Elk-1.
significantly increased COX-2 mRNA and protein expres-
sion. On the contrary, Elk-1 RNAi significantly decreased
COX-2 expression. EMSA and site-directed mutagenesis
experiments indicated that the effect of Elk-1 on COX-2
transcription involves one Elk-1 cis-element of COX-2 pro-
moter located between nucleotides −82 and −69, but not
theothertwopredictedconsensuscis-elements(−1295/−1282
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Figure 5: Elk-1 inhibited glucose-stimulated insulin secretion in
INS-1 cells. INS-1 cells were transfected with Elk-1 expression
plasmidpCMV3.0b-Elk-1oremptyvector pCMV3.0bascontrolfor
48h.Controlcellsdemonstrateda6.9-foldincreaseininsulinsecre-
tion with 16.7mM glucose, whereas Elk-1 overexpressing cells had
only a 3.6-fold increase. Elk-1 overexpressing group demonstrated
a decrease of GSIS to 52% of the control value. Each experiment
was done in triplicate and repeated three times.
∗𝑃 < 0.001 versus
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and−1819/−1806).TheseresultssuggestedthatElk-1probably
upregulates COX-2 gene expression at least partly through
Elk-1 directly binding to the −82/−69 region of COX-2
promoter.ThiswasthefirstreportthatcharacterizedtheElk-1
cis-element in COX-2 promoter.
To further investigate the role of Elk-1 on pancreatic 𝗽-
cells dysfunction, we assessed GSIS function in INS-1 cells
that overexpressed Elk-1. As expected, Elk-1 overexpressing
group demonstrated a decrease of GSIS to 52% of the control
value. This result demonstrated that Elk-1 can inhibit GSIS
in INS-1 cells. Because COX-2 plays an important role in
𝗽-cell dysfunction and Elk-1 can upregulate COX-2 gene
expression, we presumed that Elk-1 inhibits GSIS in INS-
1 cells at least partly through upregulating COX-2 gene
expression.OtherunknownmechanismsofElk-1’sinhibitory
roleonGSISremaintobedeterminedbyfurtherexperiments
such as chromatin immunoprecipitation (ChIP) sequencing,
transcriptome sequencing, and gene array.
5. Conclusions
In conclusion, our study demonstrated that transcription
factor Elk-1 efficiently upregulates the expression of COX-2
in INS-1 cells and that this may be a new explanation for the
mechanism of 𝗽-cell insulin secretion impairments by some
stimuli.OverexpressionofElk-1mayinhibitinsulinsecretion
in 𝗽-cells by causing upregulation of COX-2. These findings
will be helpful for better understanding the transcriptional
regulation of COX-2 in pancreatic 𝗽-cell. Moreover, Elk-1,
the transcriptional regulator of COX-2 expression, will be
a potential target for the prevention of 𝗽-cell dysfunction
mediated by PGE2.
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